Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 06 2022
Historique:
pubmed: 27 3 2022
medline: 18 6 2022
entrez: 26 3 2022
Statut: ppublish

Résumé

Hematopoietic cell transplantation (HCT) is a potential cure for hematologic cancer but is associated with a risk of relapse and death. Dynamic biomarkers to predict relapse and inform treatment decisions after HCT are a major unmet clinical need. To identify a quantitative characteristic of leukocyte-endothelial interactions after HCT and test its associations with patient outcomes. In this prospective single-center cohort study from June 2017 to January 2020, patients of any age, sex, race, and ethnicity who had HCT for hematologic cancer were referred by health care professionals as either suspected of having symptoms or not having symptoms of acute graft-vs-host disease between 25 and 161 days after HCT. Patients underwent noninvasive skin videomicroscopy. Videos of dermal microvascular flow were recorded with a reflectance confocal microscope. Two blinded observers (J.R.P. and Z.Z.) counted leukocytes adherent to and rolling along the vessel wall per hour (A&R). Of 57 enrolled patients, 1 relapsed before imaging and was excluded, resulting in 56 patients included in analyses. Relapse of cancer, relapse-free survival, and overall survival. Among the 56 patients (median age, 59 years; 38 [68%] male) who underwent imaging a median of 40 days after HCT, 21 had high A&R and 35 had low A&R. After correcting for the revised Disease Risk Index, patients with high A&R had higher rates of relapse (hazard ratio [HR], 4.24; 95% CI, 1.32-13.58; P = .02), reduced relapse-free survival (HR, 3.29; 95% CI, 1.26-8.55; P = .02), and reduced overall survival (HR, 3.06, 95% CI, 1.02-9.19; P = .05). These associations were preserved after correcting for possible confounders, steroid treatment, and acute graft-vs-host disease status. In the prognostic adequacy calculation by using Cox models, the new imaging biomarker (A&R) accounted for 82% to 95% of the prognostic information to predict each outcome. By contrast, the best existing clinical predictor routinely available, the revised Disease Risk Index, accounted for 10% to 28% of the prognostic information in the same model. In this cohort study, leukocyte-endothelial interactions, visualized directly in skin after HCT, were associated with the patient outcomes of relapse, relapse-free survival, and overall survival. Assessing this dynamic marker could help patients at high risk for relapse who may benefit from interventions, such as early withdrawal of immunosuppression.

Identifiants

pubmed: 35338704
pii: 2790612
doi: 10.1001/jamadermatol.2022.0924
pmc: PMC9201675
mid: NIHMS1819485
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

661-669

Subventions

Organisme : CSRD VA
ID : IK2 CX001785
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States

Références

Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182
pubmed: 32438042
Blood. 2005 Aug 15;106(4):1495-500
pubmed: 15878974
Biol Blood Marrow Transplant. 2016 Mar;22(3):449-55
pubmed: 26541363
Cancer. 2020 Jan 1;126(9):1837-1855
pubmed: 32073653
Microcirculation. 2021 Nov;28(8):e12725
pubmed: 34409720
J Leukoc Biol. 1994 May;55(5):662-75
pubmed: 8182345
J Am Coll Cardiol. 1985 May;5(5):1055-63
pubmed: 3989116
Blood Adv. 2019 Feb 12;3(3):230-236
pubmed: 30674457
Front Immunol. 2015 Nov 24;6:603
pubmed: 26635815
Br J Dermatol. 2019 Oct;181(4):829-831
pubmed: 30927259
Blood. 2018 Jun 21;131(25):2846-2855
pubmed: 29545329
Otolaryngol Clin North Am. 2010 Aug;43(4):753-68
pubmed: 20599080
Blood. 2012 Jul 26;120(4):905-13
pubmed: 22709687
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
Br J Dermatol. 2016 Aug;175(2):364-74
pubmed: 26948927
Nat Med. 2001 Mar;7(3):376-9
pubmed: 11231641
Microcirculation. 2020 Aug;27(6):e12621
pubmed: 32304109
Blood Adv. 2019 Jun 25;3(12):1881-1890
pubmed: 31221661
J Invest Dermatol. 1995 Jun;104(6):946-52
pubmed: 7769264
Leukemia. 2021 Jul;35(7):2054-2063
pubmed: 33204013
Elife. 2020 Oct 14;9:
pubmed: 33052099
Crit Care. 2018 Sep 30;22(1):240
pubmed: 30268146
Leukemia. 2020 Jul;34(7):1898-1906
pubmed: 32020045

Auteurs

Inga Saknite (I)

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia, Riga, Latvia.

James R Patrinely (JR)

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Dermatology Service and Research Service, Tennessee Valley Healthcare System, US Department of Veterans Affairs, Nashville.

Zijun Zhao (Z)

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Dermatology Service and Research Service, Tennessee Valley Healthcare System, US Department of Veterans Affairs, Nashville.

Heidi Chen (H)

Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.

Alicia Beeghly-Fadiel (A)

Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Tae Kon Kim (TK)

Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Madan Jagasia (M)

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Now withIovance Biotherapeutics, San Carlos, California.

Michael Byrne (M)

Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Eric R Tkaczyk (ER)

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Dermatology Service and Research Service, Tennessee Valley Healthcare System, US Department of Veterans Affairs, Nashville.
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH